Control of blood pressure variability in caveolin-1-deficient mice: Role of nitric oxide identified in vivo through spectral analysis

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 527-536

  Desjardins, Fanny ^a   Lobysheva, Irina ^a   Pelat, Michel ^a   Gallez, Bernard ^a   Feron, Olivier ^a   Dessy, Chantal ^a   Balligand, Jean Luc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Blood pressure; Blood pressure variability; Caveolin 1; Endothelial function; Nitric oxide

Indexed keywords

ANTENNAPEDIA PROTEIN; CAVEOLIN 1; NEUROHORMONE; NITRIC OXIDE; SERINE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FREQUENCY MODULATION; GENETICS; HOMEOSTASIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ANIMALS; AORTA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATTLE; CAVEOLIN 1; CELLS, CULTURED; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY, AMBULATORY; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FOURIER ANALYSIS; HEART RATE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; NITROPRUSSIDE; PEPTIDE FRAGMENTS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TELEMETRY;

EID: 48749108152     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn080     Document Type: Article

References (28)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
3. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997;272:25437-25440.
4. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449-2452.
5. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, Sessa WC. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA 2005;102:761-766.
6. Wunderlich C, Schober K, Lange SA, Drab M, Braun-Dullaeus RC, Kasper M et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun 2006;340:702-708.
7. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002;99:11375-11380.
8. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 2005;97:864-871.
9. Yamada Y, Ando F, Shimokata H. Association of gene polymorphisms with blood pressure and the prevalence of hypertension in community-dwelling Japanese individuals. Int J Mol Med 2007;19:675-683.
10. Grilo A, Fernandez ML, Beltran M, Ramirez-Lorca R, Gonzalez MA, Royo JL et al. Genetic analysis of CAV1 gene in hypertension and metabolic syndrome. Thromb Haemost 2006;95:696-701.
11. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals: part 2: blood pressure measurement in experimental animals: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Arterioscler Thromb Vasc Biol 2005;25:e22-e33.
12. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am J Physiol Regul Integr Comp Physiol 2000;279:R2214-R2221.
13. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002;39:710-714.
14. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003;21:1961-1967.
15. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480-2486.
16. Sbaa E, DeWever J, Martinive P, Bouzin C, Frerart F, Balligand JL et al. Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis. Circ Res 2006;98:1219-1227.
17. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.
18. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000;6:1362- 1367.
19. Dikalov S, Fink B. ESR techniques for the detection of nitric oxide in vivo and in tissues. Methods Enzymol 2005;396:597-610.
20. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000;87:999-1005.
21. Stauss HM, Godecke A, Mrowka R, Schrader J, Persson PB. Enhanced blood pressure variability in eNOS knockout mice. Hypertension 1999;33:1359-1363.
22. Stauss HM. Power spectral analysis in mice: What are the appropriate frequency bands? Am J Physiol Regul Integr Comp Physiol 2007;292:R902-R903.
23. Bertram D, Barres C, Cuisinaud G, Julien C. The arterial baroreceptor reflex of the rat exhibits positive feedback properties at the frequency of Mayer waves. J Physiol 1998;513:251-261.
24. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 2004;95:154-161.
25. Frank PG, Lisanti MP. Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Curr Opin Lipidol 2004;15:523-529.
26. Yu J, Bergaya S, Murata T, Alp IF, Bauer MP, Lin MI et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest 2006;116:1284-1291.
27. Saliez J, Bouzin C, Rath G, Ghisdal P, Desjardins F, Rezzani R et al. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 2008;117:1065-1074.
28. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.